COUR Pharmaceuticals, a clinical-stage biotechnology company developing novel immune-modifying nanoparticles designed to reprogram the immune system, appointed Dannielle Appelhans as Chief Operating Officer, effective immediately. Appelhans will oversee and execute the company’s research and development, technical development, technical operations, and quality as well as be a significant contributor to corporate strategy and other business operations. Appelhans served most recently as t...